Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis. The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combinati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sekeres, Mikkael A., Tiu, Ramon V., Komrokji, Rami, Lancet, Jeffrey, Advani, Anjali S., Afable, Manuel, Englehaupt, Ricki, Juersivich, Joyce, Cuthbertson, David, Paleveda, Jennifer, Tabarroki, Ali, Visconte, Valeria, Makishima, Hideki, Jerez, Andres, Paquette, Ronald, List, Alan F., Maciejewski, Jaroslaw P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525020/
https://ncbi.nlm.nih.gov/pubmed/22915641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-434639
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars